Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced several data presentations for mirvetuximab soravtansine...

IMGN : 4.78 (+1.70%)
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate...

IMGN : 4.78 (+1.70%)
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from an analysis of patient-reported outcomes (PROs)...

IMGN : 4.78 (+1.70%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2022, the compensation committee of the...

IMGN : 4.78 (+1.70%)
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

JAZZ : 133.29 (+0.66%)
IMGN : 4.78 (+1.70%)
CPRX : 12.83 (+1.02%)
AERI : 15.13 (+0.07%)
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ESPR : 6.70 (-2.05%)
IMGN : 4.78 (+1.70%)
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today provided an update on the pivotal Phase 2 CADENZA study of pivekimab...

IMGN : 4.78 (+1.70%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 29, 2022, the compensation committee of the...

IMGN : 4.78 (+1.70%)
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

RHHBY : 40.6200 (-1.19%)
IMGN : 4.78 (+1.70%)
IONS : 44.23 (-0.11%)
VRCA : 2.92 (+4.66%)
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript

IMGN earnings call for the period ending June 30, 2022.

IMGN : 4.78 (+1.70%)

Barchart Exclusives

Apollo Commercial Real Estate REIT's 16.9% Yield May Be a Warning
Apollo Commercial Real Estate Finance REIT now sports a 16.9% dividend yield, based on its $1.40 annual payout. But this may be the market's signal that a dividend cut is coming, so be careful. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar